The company seeks to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations, which are expected to be available in April this year. The new
Mylan will pay SEK165 per share, bringing the total value of the deal to $9.9bn including Meda’s debt. The transaction is anticipated to close by the end of
The hold comes as a result of the deaths that have occurred during the experimental trial. Patients have reportedly died of cardiac arrest and bleeding inside the skull.
In its draft guidance, the National Institute of Health and Care Excellence said that the benefits of Praluent are uncertain. The draft guidance has not recommended alirocumab, alone
The pay-for-performance agreements are expected to set pricing on certain drugs based on how they work for certain patients. In July 2015, the US Food and Drug Administration
The company said that it was informed by FDA that it will require another three months to complete its New Drug Application (NDA) review for eteplirsen. Sarepta received
Pharming entered into the original exclusive distribution agreement with Cytobioteck in May 2015 for the distribution of RUCONEST(R) in Colombia and Venezuela. Under the extended agreement, Cytobioteck will
One of these medicines, fulvestrant (Faslodex) for advanced breast cancer, was accepted following consideration under the SMC’s Patient and Clinician Engagement Process (PACE), which aims to improve patient
The recent orphan drug designations of Ampligen® for Ebola and Alferon® N for MERS viruses by the European Regulatory authorities demonstrates the global need for drugs that possess
ORION is a randomized, double-blind, placebo-controlled study exploring the metabolic effects of cenicriviroc (CVC) in obese adults (BMI greater than or equal to 30 kg/m2) with prediabetes or
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.